The 9th T-Cell Engager Therapeutics Summit explores advancements in T-cell engager therapeutics, focusing on improving efficacy, minimizing toxicity, and enhancing cancer treatment with bispecific and multispecific approaches.
Key Topics
A Novel Class of NK-cell Engagers for Tumor Targeting
Analyzing Target Selection to Maximize Efficacy Whilst Minimizing Toxicity
Humabody® VH as T-cell Enhancing Therapeutics for Immuno Oncology
The ImmTACTM Platform: Progress and Clinical Insight from the Soluble TCR-based Bispecific Approach
Reducing Key Toxicities with T Cell Engaging Bispecifics
The Promise of Next Generation T Cell Engagers for Cancer Treatment
Omid Vafa
A Novel Multispecific T Cell Engager Platform for a Better Therapeutic Window
Rational Combinations for Bispecific T-cell Engager (BiTE®) Immune Therapy in Solid Tumors
Prevention and Treatment of CRS with Bispecific Antibodies
Mechanisms of Bispecific T cell Engager Efficacy and Toxicity in Murine Tumor Models
Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs
